Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elizabeth Harden is active.

Publication


Featured researches published by Elizabeth Harden.


Annals of Pharmacotherapy | 1992

Generalized Seizures Secondary to High-Dose Busulfan Therapy:

Christopher P. Murphy; Elizabeth Harden; James M. Thompson

Two patients without prior histories of neurologic disorders experienced generalized seizures while receiving high-dose busulfan (total dose 16 mg/kg) as part of a preparative regimen for allogeneic bone marrow transplantation. A review of the literature revealed 14 similar occurrences. Maintenance of therapeutic blood concentrations of Phenytoin in subsequent patients at our institution has resulted in no further patients experiencing generalized seizures. Prophylactic anticonvulsant therapy should be considered in patients receiving high doses of busulfan.


Annals of Pharmacotherapy | 2012

Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis

Rishi Desai; Richard A. Hansen; Jaya K. Rao; Tania M Wilkins; Elizabeth Harden; Andrea Yuen; Daniel E Jonas; Robert Roubey; Beth Jonas; Gerald Gartlehner; Linda J Lux; Katrina E Donahue

BACKGROUND: Introduction of biologic disease-modifying antirheumatic drugs (DMARDs) has considerably changed treatment options for rheumatoid arthritis (RA) over the past decade. Very little information is available on comparative discontinuation rates of the biologics. OBJECTIVE: To compare treatment discontinuations for 9 biologic DMARDs in adults with RA. METHODS: We searched electronic databases through May 2012 to retrieve randomized controlled trials (RCTs) of patients with RA that compared biologic DMARDs with placebo or another biologic DMARD. The primary outcome was treatment discontinuation during the blinded phase of the trials, measured as overall withdrawals, withdrawals resulting from lack of efficacy, and withdrawals resulting from adverse events. Random-effects meta-analysis estimated the effect size for individual agents, and adjusted indirect comparisons were made between biologics using mixed treatment comparisons (MTC) meta-analysis. RESULTS: Forty-four trials were included in the analysis. In comparison with placebo, biologics were less likely to be withdrawn because of lack of efficacy (OR 0.22, 95% CI 0.17 to 0.27) and more likely to be withdrawn because of an adverse event (OR 1.41, 95% CI 1.16 to 1.70). Based on the MTC, certolizumab had the most favorable overall withdrawal profile, followed by etanercept and rituximab. Certolizumab had lower relative withdrawal rates resulting from lack of efficacy than adalimumab, anakinra, and infliximab. Anakinra had higher relative withdrawal rates resulting from lack of efficacy than most other biologics. Certolizumab and infliximab had more, while etanercept had fewer, withdrawals because of adverse events than most other drugs. CONCLUSIONS: Based on MTC using data from RCTs, differences in discontinuation rates were observed, generally favoring certolizumab, etanercept, and rituximab over other biologic DMARDs. These potential differences need to be further explored in head-to-head trials or well-conducted observational studies.


Evidence report/technology assessment | 2011

Health literacy interventions and outcomes: an updated systematic review.

Nancy D Berkman; Stacey Sheridan; Katrina E Donahue; David J. Halpern; Anthony J. Viera; Karen Crotty; Audrey Holland; Michelle Brasure; Kathleen N. Lohr; Elizabeth Harden; Elizabeth Tant; Ina Wallace; Meera Viswanathan


Cancer | 1993

Dose-related cutaneous toxicities with etoposide

Christopher P. Murphy; Elizabeth Harden; Roger H. Herzig


Archive | 2012

Drug Therapy for Rheumatoid Arthritis in Adults: An Update

Katrina E Donahue; Daniel E Jonas; Richard A. Hansen; Robert Roubey; Beth Jonas; Linda J Lux; Gerald Gartlehner; Elizabeth Harden; Tania M Wilkins; Visali Peravali; Shrikant I. Bangdiwala; Andrea Yuen; Patricia Thieda; Laura C Morgan; Karen Crotty; Rishi Desai; Megan Van Noord


Archive | 2012

Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report

Katrina E Donahue; Daniel E Jonas; Richard A. Hansen; Robert Roubey; Beth Jonas; Linda J Lux; Gerald Gartlehner; Elizabeth Harden; Andrea Yuen; Patricia Thieda; Laura C Morgan; Karen Crotty; Megan Van Noord


Evidence report/technology assessment | 2011

Health literacy interventions and outcomes

Nancy D Berkman; Stacey Sheridan; Katrina E Donahue; David J. Halpern; Anthony J. Viera; Karen Crotty; Audrey Holland; Michelle Brasure; Kathleen N. Lohr; Elizabeth Harden; Elizabeth Tant; Ina Wallace; Meera Viswanathan


Archive | 2012

Figure 7, Mixed treatment comparisons for overall withdrawals in randomized controlled trials of biologic DMARDs

Katrina E Donahue; Daniel E Jonas; Richard A Hansen; Robert Roubey; Beth Jonas; Linda J Lux; Gerald Gartlehner; Elizabeth Harden; Tania M Wilkins; Visali Peravali; Shrikant I. Bangdiwala; Andrea Yuen; Patricia Thieda; Laura C Morgan; Karen Crotty; Rishi Desai; Megan Van Noord


Archive | 2012

Criteria for Assessing the Quality of Individual Studies

Katrina E Donahue; Daniel E Jonas; Richard A Hansen; Robert Roubey; Beth Jonas; Linda J Lux; Gerald Gartlehner; Elizabeth Harden; Tania M Wilkins; Visali Peravali; Shrikant I. Bangdiwala; Andrea Yuen; Patricia Thieda; Laura C Morgan; Karen Crotty; Rishi Desai; Megan Van Noord


Archive | 2012

Mixed Treatment Comparisons Sensitivity Analysis Methods

Katrina E Donahue; Daniel E Jonas; Richard A Hansen; Robert Roubey; Beth Jonas; Linda J Lux; Gerald Gartlehner; Elizabeth Harden; Tania M Wilkins; Visali Peravali; Shrikant I. Bangdiwala; Andrea Yuen; Patricia Thieda; Laura C Morgan; Karen Crotty; Rishi Desai; Megan Van Noord

Collaboration


Dive into the Elizabeth Harden's collaboration.

Top Co-Authors

Avatar

Katrina E Donahue

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrea Yuen

Research Triangle Park

View shared research outputs
Top Co-Authors

Avatar

Beth Jonas

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Daniel E Jonas

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Linda J Lux

Research Triangle Park

View shared research outputs
Top Co-Authors

Avatar

Robert Roubey

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Patricia Thieda

University of North Carolina at Chapel Hill

View shared research outputs
Researchain Logo
Decentralizing Knowledge